Bank of America Securities analyst Jason Gerberry has reiterated their bullish stance on ARWR stock, giving a Buy rating yesterday.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Jason Gerberry has given his Buy rating due to a combination of factors reflecting Arrowhead Pharmaceuticals’ promising pipeline and strategic developments. One of the key considerations is the anticipated product launch and multiple pipeline catalysts expected in 2025. This includes the potential for high-impact muscle-related advancements, particularly with partner Sarepta’s involvement in studies for ARO-DM1 and ARO-DUX4, which could significantly enhance Arrowhead’s market position.
Furthermore, Gerberry notes the strategic timing of the plozasiran launch for the rare FCS indication, expected in December 2025, which could yield a substantial return on investment and pave the way for future developments in the larger SHTG indication. Additionally, the ongoing ARO-INHBE obesity study is expected to deliver promising data by the fourth quarter of 2024, highlighting Arrowhead’s leading role in INHBE development, potentially offering a strong proof of concept. These factors, combined with the company’s asset prioritization and capital allocation strategies, support the attractive risk/reward profile that underpins the Buy recommendation.